Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema
NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.
NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.